Celularity (CELU) EBT (2019 - 2025)
Celularity (CELU) posted quarterly EBT of -$24.4 million for Q4 2025, down 83.25% year-over-year from -$145.4 million in Q4 2024, and down 5.56% quarter-over-quarter from -$23.1 million in Q3 2025.
Celularity (CELU) EBT (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported EBT for 7 consecutive years, with -$24.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT fell 83.25% year-over-year to -$24.4 million; the TTM figure through Dec 2025 stood at -$91.7 million (down 58.42% YoY), while the FY2025 annual figure was -$91.7 million, down 58.42% from the prior year.
- EBT slipped to -$24.4 million in Q4 2025 per CELU's latest filing, from -$23.1 million in the prior quarter.
- Across five years, EBT topped out at $49.9 million in Q3 2021 and bottomed at -$93.9 million in Q3 2023.
- Historically, EBT has averaged -$21.6 million across 5 years, with a median of -$20.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBT surged 708.13% — and 2023, when it tumbled 2063.11%.
- Celularity's EBT stood at -$4.0 million in 2021, then soared by 708.13% to $24.4 million in 2022, then tumbled by 60.91% to $9.6 million in 2023, then plunged by 239.09% to -$13.3 million in 2024, then plunged by 83.25% to -$24.4 million in 2025.
- Business Quant data shows CELU's EBT at -$24.4 million in Q4 2025, -$23.1 million in Q3 2025, and -$24.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.36 Mn |
| Sep 30, 2025 | -23.08 Mn |
| Jun 30, 2025 | -24.52 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -13.29 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -6.49 Mn |
| Mar 31, 2024 | -22.01 Mn |
| Dec 31, 2023 | 9.56 Mn |
| Sep 30, 2023 | -93.88 Mn |
| Jun 30, 2023 | -47.95 Mn |
| Mar 31, 2023 | -64.02 Mn |
| Dec 31, 2022 | 24.45 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | 47.84 Mn |
| Mar 31, 2022 | -62.87 Mn |
| Dec 31, 2021 | -4.02 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | -64.48 Mn |
| Mar 31, 2021 | -81.54 Mn |